<DOC>
	<DOCNO>NCT00870649</DOCNO>
	<brief_summary>Objectives : To reduce risk S. haematobium pathology recurrence three year follow vaccine administration control safety therapeutic strategy child expose urinary schistosomiasis . Methodology : Phase III trial , self-contained , randomize , double blind , two parallel group receive 3 injection D0 , W4 , W8 boost W52 , one group receive `` Bilhvax '' , one placebo , S. haematobium infect child pretreated two dos PZQ ( W9 W8 ) Patient include : Infected school child , 6 9 year age . Primary objective : To demonstrate significant delay recurrence schistosomiasis pathology vaccine group compare control group 3 year period follow first administration ( D0 W152 ) . Secondary objective : safety Duration : February 2009 March 2012</brief_summary>
	<brief_title>Efficacy Bilhvax Association With Praziquantel Prevention Clinical Recurrences Schistosoma Haematobium</brief_title>
	<detailed_description>Patient inclusion ( detailed criterion ) : Children CI CP class public school St Louis Region ( Senegal ) A male female , include , 6 9 year age time first vaccination Free obvious health problem except schistosomiasis establish clinical examination ( W8-W1 ) Found positive S. haematobium infection selection period ( W12 à W9 ) : microhaematuria ≥ 2+ et Urinary Filtration , UF ≥ 50 egg Sh/10ml urine Written inform consent obtain parent guardian subject ( W9 ) child acceptance Pretreated 2 dos 40mg/kg PZQ ( W9 W8 ) Absence heavy lesion urinary tract echotomography ( W8 et W1 ) Primary objective ( detail ) : To demonstrate significant delay recurrence schistosomiasis pathology vaccine group compare control group 3 year period follow first administration ( D0 W152 ) . Criterion meet recurrence association : Positive microscopic haematuria ( positivity urinary stick : ≥ 1+ ) - either active visit ( W82 , W100 , W117 , W134 , W152 ) . - spontaneous complaint patient time Positive parasitological test define presence least one living egg S. haematobium one three UF ( one UF per day/3 day one week ) . The delay first recurrence define delay date inclusion date positive parasitological test . Statistical consideration : The number patient necessary detect expect difference 3 year study ( 50 % recurrence vaccinate group versus 70 % placebo group ) , statistical power 80 % bilateral test 5 % , 103 child per group . To assume lost statistical power `` intention treat '' analysis ( ITT ) result number case vaccine protocol complete , 125 child per group include study . In total 250 child include study .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Schistosomiasis</mesh_term>
	<mesh_term>Schistosomiasis haematobia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Praziquantel</mesh_term>
	<criteria>Children CI CP class public school St Louis Region ( Senegal ) A male female , include , 6 9 year age time first vaccination Free obvious health problem except schistosomiasis establish clinical examination ( W8W1 ) Found positive S. haematobium infection selection period ( W12 à W9 ) : microhaematuria ≥ 2+ et Urinary Filtration , UF ≥ 50 egg Sh/10ml urine Written inform consent obtain parent guardian subject ( W9 ) child acceptance Pretreated 2 dos 40mg/kg PZQ ( W9 W8 ) Absence heavy lesion urinary tract echotomography ( W8 et W1 ) Absence write inform consent express refusal child Vaccination study vaccine within 90 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunomodifying drug , actual since previous year . History allergic disease reaction likely exacerbate component vaccine Acute disease time enrolment Other condition opinion PI may potentially represent danger child enrol .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Schistosomiasis vaccine</keyword>
	<keyword>therapeutic vaccine</keyword>
	<keyword>Bilhvax</keyword>
</DOC>